Navigation Links
Immuno-Oncology 360° (IO360°) NYC Gathering Announces Keynotes for the 5th Annual Event

The Conference Forum announces the keynote-speaking faculty for the 5th annual Immuno-Oncology 360° summit to be held February 6-8, 2019 at the Crowne Plaza Times Square in New York City.

The opening keynote of the Translational Science and Emerging Biomarker plenary session is Genentech’s Global Franchise Leader in Cancer Immunotherapy Biomarkers and IO360° Plenary Chair, Priti Hegde, PhD. Dr Hegde will address biomarker signaling and turning cold tumors hot.

IO clinical trial pioneer, Founder and Co-Principal Investigator of I-SPY 2 and Director, Carol Franc Buck Breast Cancer Center at UCSF, Dr Laura Esserman will provide the plenary keynote for the Clinical Trial Operations in IO session on day two of the IO360° summit. Dr Esserman will share the remarkable progress achieved by the I-SPY 2 clinical trials in improving breast cancer outcomes. Dr Esserman will also share how the innovative clinical trial model is impacting beyond breast cancer by increasing efficiencies and accelerate the development of more effective therapies for a wider range of cancers and other diseases.

The most prestigious analyst in IO, Andrew Baum, MD, Head of Global Healthcare and Managing Director, Equity Research for Citi will lead the Financial and Commercial Implications plenary session. Dr Baum along with IPO experts David Epstein, MBA, Executive Partner, Flagship Pioneering and Dan Passeri, JD, President and CEO of Cue Biopharma will join forces on a panel title “Turning an Asset into Value” to share what goes into preparing for an IPO, straight licensing with the transition to a public company and decision making on prioritization within portfolios.

IO360° introduces a new plenary session on Next Generation Cell Therapy, which features talks on optimization through engineering t-cells led by the University of Pennsylvania and emerging cell therapy approaches led by GSK and Janssen Oncology.

New leadership to IO360° include: Ronald Herbst, PhD, Medimmune; Cedrik Britten, MD, GSK; Theresa LaVallee, PhD, Parker Institute for Cancer Immunotherapy; Tara Arvedson, PhD, Amgen; Jonathan Zalevsky, PhD, Nektar; Tahamtan Ahmadi, MD, PhD, GenMab; Adriana Comprelli, BMS; Aung Naing, MD, FACP, MD Anderson Cancer Center; Martin Oft, MD, ARMO; Ian Pyrah, PhD, Seattle Genetics; Marco Ruella, MD, University of Pennsylvania; Lawrence Schwartz, MD, Columbia University Medical Center; Andrea van Elsas, PhD, ADURO; Stephen Willingham, PhD, Corvus Pharmaceuticals; Anton Xavier, MBA, NYS Center for Biotechnology and Sadik Kassim, PhD, Mustang Bio; Matthew Mulvey, PhD, BeneVir.

Drug development mavericks, Roy Baynes, MD, PhD, Merck, Daniel Chen, MD, PhD, IGM Biosciences (formerly of Genentech) and Michael Kalos, PhD, Janssen (formerly of Eli Lilly) are back with provide updates on clinical developments including new cell therapy approaches and a deeper look at biomarkers and companion diagnostics for predicting response.

IO360° is divided into the following plenaries with data presentations and panel discussions on Discovery and Preclinical Science, Translational Science, Biomarkers and Diagnostics, Clinical Operations and Development, Next Generation Cell Therapy, Imaging Aspects, Business Developments, Financial and Commercial Implications, Emerging Technologies, and Trends in the Field.

“It is a privilege and honor to work with all stakeholders from pharma, biotech, academia, investors, FDA and patients to foster collaborations that lead to significant advances in Immuno-Oncology through IO360°,” says Conference Director Kate Woda.

IO360° will also feature extensive networking opportunities and includes a one-on-one partnering system to help facilitate business meetings and additional collaborations.

About Immuno-Oncology 360°:
Immuno-Oncology (IO) 360° is the premier meeting across all stakeholders in IO, addressing the rapid advancements of clinical, scientific and business developments of IO in one setting to help develop therapeutics for a wider range of cancers at an accelerated rate. Guided by lead advisors Axel Hoos, MD, PhD, SVP of Oncology R&D, GSK, James Gulley, MD, PhD, Head of Immunotherapy Section and Director of Medical Oncology Service at the Office of the Clinical Director, Center for Cancer Research, NCI and Andrew Baum, MD, Head of Global Healthcare and Managing Director, Equity Research, Citi, the three-day summit features ten plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees representing pharma, biotechs, academia, research organizations, business development and the investment community focused on IO.

About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high quality networking.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
2. Gathering information about food is not top priority for individuals with high metabolisms
3. Gathering the clues to rare gene variants contributing to schizophrenia
4. Merck Animal Health announces Vetsulin
5. AAPS announces 2013 National Biotechnology Conference award winners
6. PLOS announces Accelerating Science Award Program
7. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
8. Missouri Botanical Garden program announces collaboration with LHerboretum
9. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
10. Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
11. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
Post Your Comments:
(Date:7/11/2019)... ... July 11, 2019 , ... ... today announced a partnership with LiquiTech, a leader in Legionella prevention for ... LiquiTech will integrate Spartan’s innovative environmental DNA testing platform to provide a ...
(Date:7/9/2019)... ... 09, 2019 , ... Murrieta Genomics, a launch pad for ... founder and CEO of Tx Genetic, Helen Harrison, has spent several years researching ... connective tissue disorders. , “We are pleased and excited to join the growing ...
(Date:7/9/2019)... WILMINGTON, Del. (PRWEB) , ... July 08, 2019 ... ... Commercial Court ruled in favor of Danisco’s ownership of the innovation behind two ... argument that an entitlement action could be based on prior art was without ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... May 30, 2019 , ... ... Data Integrity on July 08-09, 2019 in Boston, MA. This peer recommended interactive ... device organizations. , The training will kick off with a compendial treatment of ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the ... Series A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and ...
(Date:5/15/2019)... Wis. (PRWEB) , ... May 16, 2019 , ... ... and water mixtures. As a result, food and beverage products rely on these ... consumers demand more natural sounding label declarations. This paradigm shift triggers food formulators ...
(Date:5/8/2019)... POWAY, Calif. (PRWEB) , ... May 07, 2019 , ... Standing at 16.2 hands, Atlas ... busy too, participating in a drill team and barrel racing, among other activities. When ... suspensory ligament. He went from being a busy horse to only being able to ...
Breaking Biology Technology: